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 I: Abstract 
 This report explores the design of an influenza vaccine manufacturing facility using a non-egg 
based expression platform. The current standard procedure in flu vaccine production is to grow the virus 
in bird eggs. However, recently there is evidence that supports production by other expression 
platforms. The Sf9 insect cell is considered in this report. Facility design including cell culture media 
formulation through product storage for shipment and final formulation is considered based on the use 
of an existing facility. The new design also employs the use of disposable equipment such as bioreactors 
and purification unit operations. These disposables help reduce production time and are an 
economically viable option. 
 Market trends are analyzed, and it is concluded that production capabilities for this proposed 
facility should be about 60 million doses per year to accommodate one third of the market and be able 
to account for potential epidemics. At this production, revenue is approximately $391 million per year. 
Capital costs are very low due to the use of the existing facility, and manufacturing costs are also very 
reasonable even with the use of disposable equipment. Based on a 10 year project lifetime, the NPV for 
the project is approximately $460 million. The project is economically robust when considering various 
factors such as fluctuating dosage selling price, dosage demand, and manufacturing costs. 
 A major concern for the profitability of this project is if the market will accept large quantities of 
vaccine produced by new methods that are not historically tested and proven to work. More research 
should conducted to determine how the market will react to such changes.  
 The next step in the design process is to conduct laboratory and pilot-scale tests to determine 
more exact cell and virus growth curves for the seed train and the bioreactors. Once this information is 
collected, more precise designs can be formulated. Based on the considerations in this report, the 
production of influenza vaccine using the Sf9 expression platform is viable both economically and in its 
ability to meet market demands in a timely manner. Companies on the leading edge of this development 
will have a great deal to gain.  
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 II: Introduction 
 Many new challenges and opportunities have arisen in the field of vaccine production in the 
twenty-first century. Increased product demand, concerns about product quality, and a greater focus on 
reducing environmental impact are a few of the challenges facing the biopharmaceutical industry [13]. 
However, with each of these challenges comes an opportunity for ingenuity and development within the 
industry. One area of increased focus within the industry has been that of developing non-egg based 
platforms for the production of influenza vaccines. The traditional expression platform for influenza 
vaccine development is bird eggs. This process has proven to be safe, reliable, and adaptable to World 
Health Organization (WHO) yearly standards. However, the egg-based platform also comes with risks 
including a potential sudden decrease in supply due to a bird flu outbreak and patient allergies to eggs 
and feathers [7]. 
 Recent developments in equipment and technology have made Chinese hamster ovary and 
insect cell expression systems realistic options for influenza vaccine production platforms [5,4]. These 
cell-based expression systems may offer increased production and faster times to market for the 
vaccines people need. The major drawback to these platforms is that they have not been used 
extensively in large-scale production like the egg-based platform. However, the initial investment of 
time, research, and financial recourses may prove to be very profitable for companies on the leading 
edge of this development.  
 This report contains preliminary design information for an existing production facility that is 
being transitioned to produce a trivalent influenza vaccine using the Sf9 insect cell expression system 
[4]. The purpose of this design report is to provide enough information for management to determine if 
this is a suitable production method to pursue. The design provides a general scope of the process from 
the preparation of cell culture media to final product purification. Final formulation and product 
packaging are mentioned but not considered in depth. Equipment specifications and process economics 
are also discussed. A brief discussion of traditional clean-in-place equipment and newer disposable 
equipment is also contained in this report. 
III: Process Description 
 The Process Flow Diagram (PFD) and overall material balance for the process are shown in 
Figure 1 below. The process consists of cell culture media preparation and scale-up seed train, virus 
inoculation and growth in production bioreactors, virus recovery and purification, and product storage. 
The product would then be shipped to the final formulation group for formulation and packaging. 
Cell Culture Media Formulation 
 There are several options for appropriate cell culture media. One option that suits the needs for 
this process is “Grace’s insect media” developed by Life TechnologiesTM. The media is prepared onsite by 
mixing media powder with water in M-101 according to the procedure provided by Life 
TechnologiesTM[9]. The mixer uses disposable pre-sterilized bags each containing 40 L of culture media. 
Seed Train 
 To begin the seed train, 1 L of culture media is added to a flask along with a vial of 1 x 107 viable 
Sf9 insect cells. The scale up process takes approximately 160 hours per batch. The cells are expanded  
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 by batch wise addition into larger volumes of media over time up to the final volume of 40 L. Over this 
time period, the cells are incubated to provide maximum growth rate. Once the final scale-up is 
completed, the mixture is ready for the production bioreactor. 
Production Bioreactor 
 The Sf9 culture broth is added to the bioreactor and inoculated with the particular strand of 
influenza virus being used in the batch. Although the vaccine being produced is trivalent, only a single 
moiety of the vaccine can be produced in each batch. The bioreactor (R-101) uses disposable 50 L bags 
to contain each 40 L batch. Each batch remains in the bioreactor for 50 hours. For the purposes of this 
design it was assumed that the Sf9 cells follow a typical growth curve as shown below in Figure 2 [1]. 
 
Figure 2: Typical cell density growth curve for Sf9 insect cells in a batch culture [1] 
The first 160 hours represent scale-up in the seed train. Inoculation occurs at the 160 hour 
point. The next 50 hours account for virus production in the bioreactor. The broth is removed from the 
bioreactor at 210 hours. Again, this setup is based on a typical growth curve for Sf9 cells. If this 
production method is pursued, it would be quite necessary to employ laboratory and pilot scale 
operations to determine growth rates in the specific equipment used for this process as well as 
optimum conditions for the seed train scale-up and virus production in the bioreactor. 
Recovery, Purification, and Inactivation of Product 
 Three unit operations are used for recovery and purification of the product. Normal-flow 
filtration (S-101) is first used to remove the biomass from the product. Cross-flow filtration is then used 
to begin the purification process. Anion exchange chromatography (S-103) is used to complete the 
purification process. This method is widely accepted in the vaccine production industry and 
recommended specifically by GE HealthcareTM[3]. 
 For the inactivation process, it is necessary to select a method that safely inactivates the virus 
without destroying the product. The method used in this design is sterile filtration (S-104). Each of the 
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 purification and inactivation techniques employ disposable cartridges rather than traditional clean-in-
place vessels. 
Storage and Shipment 
 The final product from each batch will be freeze dried for proper storage according to CDC 
recommendations [12]. The product will be stored in its individual moieties. At this point in the process, 
the moiety products will be ready for shipment to the final formulation group as the market demands. 
Final formulation of the trivalent vaccine and packaging for patients will occur at this point. This final 
step in the process is outside the scope of this report and can be handled by the professionals in the 
formulation group as demand requires. 
Production Waste 
 This report investigates using a current facility for a new method of production. Therefore, it is 
assumed that the current sewer system and “kill tank” systems can be employed for the safe and 
reliable handling of all production waste from this process. 
Sample Analysis 
 Sample analysis and quantification is extremely important to maintain product quality. 
Equipment designed for this purpose may be available on site. If not, the Biacore T200 manufactured by 
GE HealthcareTM is a viable option. 
Batch Scheduling 
 The rate-limiting steps in the production process are the seed train and the bioreactors. 
Therefore, a general scheduling procedure can be outlined from these two steps in the process. A 
sample batch schedule for the seed train and bioreactor is shown below in Figure 3. The time required 
to produce the total required amount of a single moiety is approximately 35 days (840 hours). The time 
required to produce all of the required moieties is approximately 105 days. 
 
Figure 3: Sample seed train and bioreactor batch schedule for the complete production cycle of a single moiety 
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  The time required for the seed train for each batch is 160 hours. In addition, it is assumed that 8 
hours of cleaning, sterilizing, and preparing for the new batch will be required for each batch since 
traditional clean-in-place vessels are used in this part of the process. The time required in the bioreactor 
is 50 hours. With a 6 hour time period between each batch, the time in the bioreactor is one third of the 
time required in the seed train. Therefore, production time can be optimized by having three 
independent seed trains running at once. This is reflected by seed trains A, B, and C in Figure 3. The 
sequence for each batch in the bioreactor is also shown in Figure 3. The three independent seed trains 
are not indicated in the PFD in Figure 1 because this diagram is designed on a “per batch” basis. 
Disposable Equipment vs. Clean-in-Place Equipment 
 There has been a recent shift in biopharmaceutical manufacturing towards disposable 
equipment [8]. Advantages of this technology include reduced capital investments, faster facility 
construction and launch, and reductions in time and costs for equipment sterilizations. However, 
traditional clean-in-place equipment has been proven effective for many years and requires a 
significantly lower consumables budget for manufacturing. The process design in this report employs 
both traditional and disposable equipment. Clean-in-place vessels are used in the seed train. Most other 
parts of the process use disposable equipment for the reasons outlined above. As this new equipment 
becomes more popular and widespread, production costs will likely decrease which will help eliminate 
the major drawback of a much greater consumables budget. 
IV: Utility Requirements 
 One major advantage of using disposable equipment is the elimination of steam required for 
cleaning and sterilizing process vessels. The major utility requirements for this facility would be water 
and power. The power requirements for the facility are not estimated in this report because the cost is 
assumed to be insignificant at this stage in the design process. Further investigation into utility costs can 
be done if plans for this facility advance in the future. Water requirements are estimated and accounted 
for in the economics section of this report. 
V: Equipment Specifications 
 The equipment specification sheet is shown on the next page in Figure 4. This specification sheet 
represents the necessary purchases for transitioning the facility to a non-egg based expression platform. 
Other equipment is required for the process but is assumed to be on site. This includes sample analysis 
equipment, “kill tank” systems for pre-sewage treatment, and miscellaneous equipment. Other 
equipment required for purchase that is not included in the PFD or equipment specifications sheet is a 
number of small flasks for the seed train scale-up procedure. 
 The bioreactors and separation equipment were all chosen from GE Healthcare’s line of 
disposable vaccine production equipment. Purchasing the majority of the equipment from a single 
manufacturer will improve compatibility and customer service should any issues arise. 
VI: Equipment Cost and Fixed Capital Investment Summary 
 Since the facility for this production process already exists, the Fixed Capital Investment (FCI) for 
this project will consist of only new capital equipment purchases. A summary of the capital costs for this  
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Figure 4: Equipment specification sheet 
process is given on the next page in Table 1. The prices are based on online prices or direct quotes from 
the manufacturer. 
 The total FCI for the process is $1 million. This number is obviously low for a pharmaceutical 
facility, but it should be considered that the vast majority of the FCI would have been incurred in the 
purchase of land and building of the actual facility. The most significant costs are the freeze dryer, 
sample analysis equipment, and bioreactor. 
VII: Manufacturing Costs 
 A summary for the annual manufacturing costs for the process is given on the next page in Table 
2. The total annual Cost of Manufacturing (COM) is $2.8 million. The largest piece of that total by far is 
the operating labor costs due to the extremely precise nature of the process. Prices for Grace’s insect 
media and disposable equipment were found online. The price of water was set to the standard value. 
Operating labor costs were calculated as outlined in Turton’s process design text [11].  
Mixers Separators
M-101 S-101
WAVE mixer manufactured by GE Ulta Prime GF manufactured by GE
Dimensions: 0.50 m x 0.38 m x 0.17 m Normal flow filtration
Maximum operating volume: 35 L Area: 0.56 square meters
Use M*Bag Pore size: 0.6 micron
     Volume: 35 L Glass microfiber filtration membrane
     Material: Plastic 10 inch capsule length
Reactors S-102
R-101 AKTAcrossflow manufactured by GE
WAVE bioreactor manufactured by GE Cross flow filtration
Stainless steel Dimensions: 0.62 m x 0.40 m x 0.65 m
Dimensions: 1.85 m x 1.09 m x 1.12 m Use AXM/AXH ultrafiltration cross flow cartridges
Use Cellbag Bioreactors      Material: polysulfone
     Volume 50 L      Membrane area: 42 square cm
     Material: Plastic S-103
Special Purpose Equipment AKTA Ready Flow Kit manufactured by GE
SP-101 A/B/C, 102 A/B/C* Ion (anion) exchange chromatography
Incubator manurfactured by Cole-Parmer Use Capto Q chromatography cartridges
Stainless steel      Bed dimensions: 80 mm x 200 mm
Temperature range: 5 C to 105 C      Highly cross-linked agarose matrix
Capacity: 24.79 cuft S-104
Chamber dimensions: 39.5 in x 52.6 in x 20.6 in Ulta Pure SG
*There are 6 total incubators employed simultaneously, Sterile Filtration
but only 2 are used on a per batch basis Area: 0.047 square meters
Refrigeration Pore size: 0.2 micron
E-101 Polyethersulphone membrane material
HM LY series pharmaceutical vacuum freezing dryer
Manufactured by HM Pharmachine
Condenser temperature: -70 C
Cooling rate: 20 to 40 C per 45 min
220 V
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Table 1: Summary of the FCI for the new vaccine production process 
 
Table 2: Summary of annual manufacturing costs for the new vaccine production process 
 
VIII: Market Conditions and Revenue Analysis 
Demand for influenza vaccine has increased sharply over the past decade as shown in Figure 5 
[6]. The CDC reports that in the 2013-2014 flu season about 145 million vaccine doses will be produced 
[10]. If this trend continues for the next flu season, it is reasonable to assume that about 150 million 
doses of vaccine will be produced in the 2014-2015 season. To support one third of the market, a major 
pharmaceutical company could produce about 50 million doses of vaccine. To account for a potential 
epidemic, production capabilities should be at 60 million doses. This assumption of 60 million doses 
produced will be carried through the rest of the economic analysis in this report. The calculation method 
for determining the number of batches to process to account for 60 million doses is shown in Appendix 
A. 
 The base revenue for this facility is determined simply by the number of doses produced 
multiplied by a constant selling price per dose. According to the CDC, the flu vaccine price per dose is 
about $10.85 [2]. Assuming a wholesale rate of 60% of that market price, the price per dose of vaccine 
Item Total Quantity Unit Cost Total Cost
WAVE Mixer 1 9,889.00$          9,889.00$           
Spinner Flasks (6L) 30 950.00$              28,500.00$         
Incubator 6 8,900.00$          53,400.00$         
WAVE bioreactor 1 190,190.00$     190,190.00$      
Cross Flow Filtration Machine 1 81,102.00$        81,102.00$         
Chromatography add-on for CFF machine 1 8,100.00$          8,100.00$           
Sample analysis machine 1 367,400.00$     367,400.00$      
Freeze dryer 1 200,000.00$     200,000.00$      
Freezer 2 9,833.00$          19,666.00$         
Total 958,247.00$      
Item Total Quantity Unit Cost Total Cost
Grace's Insect Media 108.00$                87.00$                9,396.00$               
WAVE Mixer M*Bags 36.00$                  122.00$              4,392.00$               
Reactor cellbags (50L) 36.00$                  233.00$              8,388.00$               
Normal Flow Filters 36.00$                  224.00$              8,064.00$               
Cross Flow Filtration Cartridges 72.00$                  216.00$              15,552.00$             
Chromatography cartridges 36.00$                  11,832.00$        425,952.00$           
Sterile filtration cartridges 36.00$                  388.00$              13,968.00$             
Water for Injection (L) 1,800.00$            1.00$                  1,800.00$               
Operating labor 2,018,857.00$       
Sterilization 347,000.00$           
Total 2,853,369.00$       
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 sold would be $6.51. Using this constant price and a value of 60 million doses, yearly revenue would be 
$391 million. 
 
 
Figure 5: Market trend of influenza vaccine supply and distribution since 2003 [6] 
IX: Economics Analysis 
 The analysis presented here is based on a 10 year project lifetime with one year of setup 
required. An internal rate of return (IRR) of 50% is used along with a tax rate of 40%. A working capital of 
30% of the FCI is used. The economic analysis for this base case scenario is presented below in Table 3. 
Years 5-8 were removed from the chart for the purposes of this report. The full economic analysis chart 
is available in Appendix B. The analysis folows the method outlined in Turton’s process design text [11]. 
Table 3: Base case economic analysis for the proposed production facility 
 
 The net present value (NPV) for the project is $459 million after a 10 year lifetime. This is quite 
impressive, but again it must be considered that the capital costs are considerably low due to the use of 
an existing facility. Even so, it is clear that the new production process outlined in this report is quite 
profitable.  
Sensitivity Analyses 
 It is also important to consider the proposed project’s sensitivity to market conditions as well as 
to the assumptions made in this report about the design. Figure 6 below shows the project’s economic 
sensitivity to three key factors: reduction in product selling price, reduction in the number of doses sold, 
and increased cost of manufacturing. A reduction in selling price has the expected effects with a 50% 
decrease in price resulting in about a 50% decrease in NPV. However, it is unlikely that such a price 
End of Year (k) 0 1 2 3 4 9 10 11
Investment (958,247.00)$        -$                                     -$                                   -$                                     -$                                    -$                                   -$                                   
Depreciation (dk) -$                         191,649.40$                      306,639.04$                    183,983.42$                      110,390.05$                     -$                                   -$                                   -$                                    
FCIL-∑dk -$                         766,597.60$                      459,958.56$                    275,975.14$                      165,585.08$                     958,247.00$                    958,247.00$                    958,247.00$                     
Revenue -$                         390,600,000.00$              390,600,000.00$            390,600,000.00$             390,600,000.00$             390,600,000.00$            390,600,000.00$            390,600,000.00$            
COM -$                         2,853,369.00$                   2,853,369.00$                2,853,369.00$                  2,853,369.00$                  2,853,369.00$                 2,853,369.00$                2,853,369.00$                 
(R-COM-dk)*(1-t)+dk -$                         232,724,638.36$              232,770,634.22$            232,721,571.97$             232,692,134.62$             232,647,978.60$            232,647,978.60$            232,647,978.60$            
Cash Flow (CF) (958,247.00)$        232,724,638.36$              232,770,634.22$            232,721,571.97$             232,692,134.62$             232,647,978.60$            232,647,978.60$            232,647,978.60$            
Cumulative CF (958,247.00)$        231,766,391.36$              464,537,025.58$            697,258,597.55$             929,950,732.17$             2,093,256,859.20$        2,325,904,837.80$        2,558,552,816.40$         
Discounted CF (958,247.00)$        155,149,758.91$              103,453,615.21$            68,954,539.84$                45,963,878.44$               6,051,707.82$                 4,034,471.88$                2,689,647.92$                 
Cumulative Discounted CF (958,247.00)$        154,191,511.91$              257,645,127.11$            326,599,666.96$             372,563,545.40$             452,378,195.34$            456,412,667.22$            459,102,315.14$            
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 fluctuation would occur in this market, so this will not be much of a factor on the project’s profitability. 
The number of doses sold could fluctuate somewhat if demand did not increase yearly as expected. 
Again, though, this is a very stable market with a stable client base, and the number of doses sold is 
unlikely to drop by a significant amount. The key point to consider here is that while the market is stable 
for the current production process, it is yet unclear if the market will react favorably to a new 
production method or if the market will be slow to accept a new production method as safe and 
reliable. This could potentially lower the amount of doses that this project would be able to move in the 
market and thus reduce profit. 
 The most important factor to examine is the cost of manufacturing. Some assumptions have 
been made in this report in regards to the manufacturing process especially in determining how many 
batches of product will be needed per year. The validity of these assumptions has not been tested 
experimentally. This leaves uncertainty in the manufacturing cost calculations. Figure 6 shows that the 
process is extremely robust in this area, though. A 50% increase in manufacturing costs has almost no 
effect on the NPV. Even if costs were greatly understated, this should not affect the profitability of the 
project. 
 The new production method seems to be economically profitable and robust. As long as the 
market is thought to be open to new technologies and methods of production, project profitability 
should not be a cause for concern for the Sf9 production platform. 
 
Figure 6a 
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Figure 6b 
 
Figure 6c 
Figure 6: Sensitivity of project NPV to a) price of vaccine on the market, b) number of doses sold, and c) manufacturing costs 
X: Safety, Health, and Environmental Considerations 
 There are major health and safety concerns when dealing with vaccine production. However, 
most of these concerns will not be new to the production facility simply because the expression 
platform changes. Current operating procedures will be sufficient to handle most of the changes that 
would occur. The cell culture media is chemically defined, so the facility will be animal free. The 
production team will require additional training and development for using the new single-use 
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 disposable equipment. Disposal procedures will need to be established to ensure safe disposal of all 
single-use equipment. Existing waste management systems may prove sufficient for the new process. 
However, preliminary tests should be conducted to ensure safe and reliable waste management. Facility 
sterilization is still budgeted into the design economics as a safety measure even though most of the 
equipment used in this design would be pre-sterilized single-use disposables. 
XI: Conclusions and Recommendations 
1. Influenza vaccine production by non-egg based platforms is a reasonable design consideration 
based on its ability to meet and exceed market demand in a reasonable time period and its 
economic viability. 
2. Production of 60 million doses of influenza vaccine using an Sf9 insect cell expression platform 
can be completed in three to four months economically in a facility similar to the design 
proposed in this report. 
3. Disposable equipment offers a viable alternative to traditional clean-in-place equipment. It is 
easy to use, can decrease production times, and was not shown to have a major negative 
economic impact on the design. The design herein employs disposable reactors, mixers, and 
filtration equipment. 
4. Considering recent market trends in the supply and distribution of the influenza vaccine, 
production capabilities should be 60 million doses per year to control one third of the market 
and be prepared to meet market needs during an outbreak. 
5. Capital costs in this report are quite low due to the use of an existing facility. This should be 
taken into account when considering the overall profitability of the project. 
6. The economic analysis for the project is favorable with a NPV potential of $460 million for a 10 
year project lifetime at a 50% IRR. 
7. The project is economically robust in regards to selling price and manufacturing costs. 
8. More research should be done on how the market will react to a new production method that is 
not “time-tested.” Even if production rate is not a problem, moving the vaccine in the market 
may be an issue using this new technology. 
9. Few new safety considerations arise with the transition to an Sf9 expression platform. The 
production team should be trained on any new disposable equipment employed in the process. 
10. Existing waste treatment protocols should be tested with the new production method to see if 
new equipment or protocol is required. 
11. The next step in the design process is to conduct laboratory and pilot-scale tests to determine 
more exact cell growth and virus growth profiles for more detailed designs in the future. 
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 XIV: Appendix A – Calculation Methodologies for Production  
The density of the broth exiting the reactor was given as 1.06 g/mL. The assumption was made 
that 1.00 g/mL could be accounted for by water, and that 0.02 g/mL could be accounted for by the cells 
and the virus in the broth. The radius of an Sf9 cell is estimated at 16 μm before inoculation and 20 μm 
when the virus is present in the cell [1]. The increase in volume is attributed to the virus, and a 
percentage of the amount of virus in the cells is calculated to be 0.488. Assuming that 80% of the virus 
produced in the reactor is active, the virus density is calculated by multiplying the overall density by the 
infection rate and the percent virus to give a virus density of 0.0078 g/mL. Knowing that 60 μg of each 
moiety is required per dose, the doses per mL of broth is calculated to be 130. The total dose production 
allows for the calculation of total broth production. The volume of broth per batch is also known which 
leads to the calculation of 12 batches per moiety for a total batch count of 36 for the trivalent vaccine. 
The calculation is outlined in Table A-1 below. 
Table A-1: Calculation methodology for determining the total number of batches required to meet 
production requirements 
 
 In addition, since each seed train and bioreactor cycle take 210 hours combined and there are 
12 batches per moiety and 3 available seed train batches at once, the total time for a single moiety 
production is 840 hours (35 days). 
 
 
 
 
 
Amount Unit
Total broth density 1.06 g/mL
Density of cells and virus 0.02 g/mL
Sf9 cell radius pre-virus 16 um
Sf9 cell radius inoculated 20 um
Sf9 cell volume pre virus 17148.59 um^3
Sf9 cell volume inoculated 33493.33 um^3
Volume of virus 16344.75 um^3
Percentage virus 0.488 ---
Active virus fraction 0.8 ---
Active virus density 0.007808 g/mL
Moeity required for each dose 6.00E-05 g/mL
Doses per mL of broth 130.13 dose/mL
Total doses needed 6.00E+07 dose
Broth needed 4.61E+05 mL
Volume broth per batch 40000 mL
Batches required (each moeity) 11.53 batch
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 XV: Appendix B - Complete Economics Analysis Table 
Table B-1: Complete economics analysis table 
 
 
End of Year (k) 0 1 2 3 4 5
Investment (958,247.00)$        -$                                     -$                                   -$                                     -$                                    -$                                   
Depreciation (dk) -$                         191,649.40$                      306,639.04$                    183,983.42$                      110,390.05$                     110,390.05$                    
FCIL-∑dk -$                         766,597.60$                      459,958.56$                    275,975.14$                      165,585.08$                     55,195.03$                       
Revenue -$                         390,600,000.00$              390,600,000.00$            390,600,000.00$             390,600,000.00$             390,600,000.00$            
COM -$                         2,853,369.00$                   2,853,369.00$                2,853,369.00$                  2,853,369.00$                  2,853,369.00$                 
(R-COM-dk)*(1-t)+dk -$                         232,724,638.36$              232,770,634.22$            232,721,571.97$             232,692,134.62$             232,692,134.62$            
Cash Flow (CF) (958,247.00)$        232,724,638.36$              232,770,634.22$            232,721,571.97$             232,692,134.62$             232,692,134.62$            
Cumulative CF (958,247.00)$        231,766,391.36$              464,537,025.58$            697,258,597.55$             929,950,732.17$             1,162,642,866.79$        
Discounted CF (958,247.00)$        155,149,758.91$              103,453,615.21$            68,954,539.84$                45,963,878.44$               30,642,585.63$              
Cumulative Discounted CF (958,247.00)$        154,191,511.91$              257,645,127.11$            326,599,666.96$             372,563,545.40$             403,206,131.03$            
6 7 8 9 10 11
-$                                   -$                                    -$                              -$                              -$                                
55,195.03$                      -$                                    -$                              -$                              -$                                -$                               
(0.00)$                               (0.00)$                                (0.00)$                          958,247.00$               958,247.00$                 958,247.00$                
390,600,000.00$            390,600,000.00$            390,600,000.00$       390,600,000.00$       390,600,000.00$         390,600,000.00$        
2,853,369.00$                2,853,369.00$                 2,853,369.00$           2,853,369.00$           2,853,369.00$             2,853,369.00$            
232,670,056.61$            232,647,978.60$            232,647,978.60$       232,647,978.60$       232,647,978.60$         232,647,978.60$        
232,670,056.61$            232,647,978.60$            232,647,978.60$       232,647,978.60$       232,647,978.60$         232,647,978.60$        
1,395,312,923.40$        1,627,960,902.00$         1,860,608,880.60$   2,093,256,859.20$   2,325,904,837.80$     2,558,552,816.40$    
20,426,452.16$              13,616,342.60$               9,077,561.73$           6,051,707.82$           4,034,471.88$             2,689,647.92$            
423,632,583.19$            437,248,925.79$            446,326,487.52$       452,378,195.34$       456,412,667.22$         459,102,315.14$        
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